Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304) Published in Future Oncology (Ahead of Print, 2025)

Great to see @anzuptrials.bsky.social #ENZAMET study feature in two Plain Language Summaries this month: bit.ly/4jpkxeh & bit.ly/40qTC9e #ProfChristopherSweeney @profiand.bsky.social #NHMRCCTC @cancertrialsie.bsky.social @cctg.bsky.social @astellaspharma.bsky.social #CancerAustralia